<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Can Liver J</journal-id><journal-id journal-id-type="iso-abbrev">Can Liver J</journal-id><journal-id journal-id-type="pmc-domain-id">4219</journal-id><journal-id journal-id-type="pmc-domain">canlivj</journal-id><journal-id journal-id-type="publisher-id">canlivj</journal-id><journal-title-group><journal-title>Canadian Liver Journal</journal-title></journal-title-group><issn pub-type="epub">2561-4444</issn><publisher><publisher-name>University of Toronto Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC9235128</article-id><article-id pub-id-type="pmcid-ver">PMC9235128.1</article-id><article-id pub-id-type="pmcaid">9235128</article-id><article-id pub-id-type="pmcaiid">9235128</article-id><article-id pub-id-type="pmid">35989890</article-id><article-id pub-id-type="doi">10.3138/canlivj-2021-0005</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Characterizing risk behaviour and reinfection rates for successful programs to engage core transmitters in HCV elimination (C-RESPECT)</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Conway</surname><given-names initials="B">Brian</given-names></name><degrees>MD</degrees><role content-type="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="AFF1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cor1" ref-type="corresp"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Smyth</surname><given-names initials="D">Dan</given-names></name><degrees>MD</degrees><role content-type="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="AFF2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Thomas</surname><given-names initials="R">R&#233;jean</given-names></name><degrees>MD</degrees><role content-type="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="AFF3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wong</surname><given-names initials="A">Alex</given-names></name><degrees>MD</degrees><role content-type="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="AFF4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sebastiani</surname><given-names initials="G">Giada</given-names></name><degrees>MD</degrees><role content-type="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="AFF5" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cooper</surname><given-names initials="C">Curtis</given-names></name><degrees>MD</degrees><role content-type="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="AFF6" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shah</surname><given-names initials="H">Hemant</given-names></name><degrees>MD</degrees><role content-type="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="AFF7" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kumar</surname><given-names initials="R">Ritesh</given-names></name><degrees>PhD</degrees><role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><xref rid="AFF8" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Deutsch</surname><given-names initials="G">Gretty</given-names></name><degrees>MD</degrees><role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><xref rid="AFF9" ref-type="aff">
<sup>9</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Watson</surname><given-names initials="T">Ted</given-names></name><degrees>PhD</degrees><role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role content-type="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><xref rid="AFF9" ref-type="aff">
<sup>9</sup>
</xref></contrib><on-behalf-of>the C-RESPECT Investigators</on-behalf-of></contrib-group><aff id="AFF1">
<label><sup>1</sup></label>Vancouver Infectious Diseases Centre, Vancouver, British Columbia, Canada</aff><aff id="AFF2">
<label><sup>2</sup></label>Centre for Research, Education and Clinical Care of At-Risk Populations (RECAP), Moncton, New Brunswick, Canada</aff><aff id="AFF3">
<label><sup>3</sup></label>Clinique L&#8217;Actuel, Montreal, Quebec, Canada</aff><aff id="AFF4">
<label><sup>4</sup></label>Saskatchewan Health Authority, Regina, Saskatchewan, Canada</aff><aff id="AFF5">
<label><sup>5</sup></label>McGill University Health Centre, Montreal, Quebec, Canada</aff><aff id="AFF6">
<label><sup>6</sup></label>Ottawa Hospital Research Institute, Ottawa, Ontario, Canada</aff><aff id="AFF7">
<label><sup>7</sup></label>University Health Network, Toronto, Ontario, Canada</aff><aff id="AFF8">
<label><sup>8</sup></label>Merck &amp; Co., Inc., Kenilworth, New Jersey, USA</aff><aff id="AFF9">
<label><sup>9</sup></label>Merck Canada Inc., Kirkland, Quebec, Canada</aff><author-notes><corresp id="cor1">Correspondence: Brian Conway, Vancouver Infectious Diseases Centre, 201-1200 Burrard Street, Vancouver, British Columbia V6Z 2C7 Canada. Telephone: 604-642-6429. E-mail: <email>brian.conway@vidc.ca</email></corresp></author-notes><pub-date date-type="collection" publication-format="electronic"><season>Fall</season><year>2021</year><string-date>Fall 2021</string-date></pub-date><pub-date publication-format="electronic" date-type="pub" iso-8601-date="2021-11-11"><day>11</day><month>11</month><year>2021</year><string-date>November 11, 2021</string-date></pub-date><pub-date publication-format="electronic" date-type="preprint" iso-8601-date="2021-06-10"><day>10</day><month>6</month><year>2021</year><string-date>June 10, 2021</string-date></pub-date><volume>4</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">411051</issue-id><fpage>346</fpage><lpage>359</lpage><history><date date-type="received" iso-8601-date="2021-03-14"><day>14</day><month>3</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-03-14"><day>14</day><month>3</month><year>2021</year></date></history><pub-history><event event-type="pmc-release"><date><day>11</day><month>11</month><year>2021</year></date></event><event event-type="pmc-live"><date><day>18</day><month>08</month><year>2022</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-10-21 14:25:17.980"><day>21</day><month>10</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2021 Canadian Association for the Study of the Liver</copyright-statement><copyright-year>2021</copyright-year></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="canlivj-2021-0005.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="canlivj-2021-0005.pdf"/><abstract><title>Abstract</title><sec><title>BACKGROUND</title><p>Development of robust treatment programs among core transmitters (CT) of hepatitis C virus (HCV) are needed, including strategies to address reinfection risk. The aim of this study was to describe the effectiveness of direct-acting antiviral (DAA) treatment in CT versus non-CT populations and assess reinfection rates after successful treatment.</p></sec><sec><title>METHODS</title><p>Characterizing Risk Behaviour and Reinfection Rates for Successful Programs to Engage Core Transmitters in HCV Elimination (C-RESPECT) was a prospective, observational study of HCV-infected Canadian adult patients (genotypes 1, 3, and 4) treated with DAAs between 2017 and 2020.</p></sec><sec><title>RESULTS</title><p>The full analysis set included 429 participants (259 CT, 170 non-CT). Key differences were observed in baseline profiles: CT participants were younger (mean 42.3 [SD 11.2] y versus 55.0 [SD 11.1] y, respectively) and reported higher rates of social assistance (35.7% versus 14.8%), smoking (83.7% versus 52.4%), low socioeconomic status (yearly income &lt;$15,000: 69.6% versus 43.9%), illicit drug use (83.7% versus 34.3%), and previous incarcerations (62.7% versus 36.9%). DAA treatment adherence was similar; 93 .5% versus 98.3% of CT versus non-CT participants completed the assigned treatment duration. Cure rates (sustained virologic response) were comparable, ranging from 94.9% to 98.1%. All reinfections were among CT participants, with a rate of 13.8/100 person-years (95% CI 9.2&#8211;20.8) with mean time to reinfection of 24.6 (SD 0.6) months;</p></sec><sec><title>CONCLUSIONS</title><p>CT and non-CT participants respond equally well to DAA treatment; however, with some reinfections among CT participants. Innovative multidisciplinary programs must be developed to mitigate this risk in this key population.</p></sec></abstract><kwd-group><title>Keywords:</title><kwd>Canada</kwd><x xml:space="preserve">; </x><kwd>core transmitter</kwd><x xml:space="preserve">; </x><kwd>cure</kwd><x xml:space="preserve">; </x><kwd>direct-acting antivirals</kwd><x xml:space="preserve">; </x><kwd>HCV</kwd><x xml:space="preserve">; </x><kwd>hepatitis C virus</kwd><x xml:space="preserve">; </x><kwd>observational</kwd><x xml:space="preserve">; </x><kwd>real-world evidence</kwd><x xml:space="preserve">; </x><kwd>reinfection</kwd><x xml:space="preserve">; </x><kwd>sustained virologic response</kwd></kwd-group><funding-group><award-group><funding-source>Merck Canada Inc., Kirkland, Quebec, Canada</funding-source></award-group><funding-statement>This study was sponsored and funded by Merck Canada Inc., Kirkland, Quebec, Canada.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>